ArticleVeterinarni medicina2026
Secondary antibody therapy outperforms corticosteroids in an ameliorating lipopolysaccharide-induced rat model of premature ovarian failure.
Article in Veterinarni medicina, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Premature ovarian failure (POF) is a significant cause of infertility and is often linked to autoimmune aetiologies. Lipopolysaccharide (LPS)-induced inflammation is a well-established model of autoimmune POF in rodents. Immunomodulatory treatments involving corticosteroids, frankincense, and targeted secondary antibodies have been hypothesised to mitigate the autoimmune response, reduce anti-ovarian antibody (AOA) levels, and restore ovarian function in an LPS-induced POF rat model. A POF model was established in female albino rats via the intraperitoneal injection of LPS. The rats were then divided into groups that received no treatment (LPS control), dexamethasone (DEX-treated LPS-treated rats), methylprednisolone (MP-treated LPS-treated rats), frankincense (Frankincense-treated LPS-treated rats), or secondary anti-ovarian antibodies (secondary Ab-treated LPS-treated rats) for 3 to 4 weeks. The serum levels of AOA, 17β-oestradiol, follicle-stimulating hormone (FSH), and luteinising hormone (LH) were assayed via commercial enzyme-linked immunosorbent assay (ELISA) kits. Ovarian tissues were examined histopathologically to assess structural damage and recovery. LPS induction successfully created a POF phenotype, as evidenced by significantly elevated AOA levels (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.